National Community Pharmacists Association
FDANonrulemakingFDA-2009-N-0143

Risk Evaluation and Mitigation Strategies for Certain Opioid Drugs

RIN
Last modified
Jan 5, 2022
Comment window
closed 5761d ago
National Community Pharmacists Association filings
2

Activity

National Community Pharmacists Association filed 2 comments on this docket between Jul 6, 2009 and Oct 29, 2010. 47 other organizations filed here. The comment window closed 5761d ago.

What National Community Pharmacists Association filed (2)

Oct 29, 2010· National Community Pharmacists Association (NCPA)- Comment· FDA-2009-N-0143-1212

October 19, 2010 Division of Dockets Management HFA-305 Food and Drug Administration 5630 Fishers Lane Room 1061 Rockville, MD 20852 Subject: Risk Evaluation and Mitigation Strategies for Certain Opioid Drugs: Docket FDA-2009-N-0143-1187 To Whom It May Concern: Please find submissions from the National Community Pharmacists Association (NCPA) regarding the request for comments for the development of a REMS program for opioid drugs. The National Community Pharmacists Association (NCPA) represents America's community pharmacists, including the owners of more than 23,000 community pharmacies, pharmacy franchises and chains. Together, these employ over 300,000 full-time employees and dispense nearly half of the nation's retail prescription medicines. Attached please find several documents which outline our views on these issues. We appreciate the opportunity to be part of the public comment process regarding this important patient care issue. Thank you. Sincerely, John M. Coster, Ph.D., RPh. Senior Vice President, Government Affairs

Jul 6, 2009· National Community Pharmacists Association (NCPA) - Comment· FDA-2009-N-0143-1017

Filed on regulations.gov — full text not in the inline record.

Abstract

No abstract recorded.

View on regulations.gov →
Risk Evaluation and Mitigation Strategies for Certain Opioid Drugs (FDA) — National Community Pharmacists Association | OpenPolis